Literature DB >> 21630023

A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.

Seung Jin Kim1, Akinori Masago, Yasuhiro Tamaki, Kenji Akazawa, Fumine Tsukamoto, Jun Sato, Toshiyuki Ozawa, Yukio Tsujino, Shinzaburo Noguchi.   

Abstract

The aim of this study was to develop a new method for detecting circulating tumor cells (CTCs) in breast cancer patients by using the telomerase-specific replication-selective adenovirus OBP-401. Once transfected, OBP-401 can replicate only in telomerase expressing cells and emit fluorescence as it replicates so that the transfected cells become easily recognizable. Peripheral blood samples were drawn from 50 metastatic breast cancer patients and 27 early breast cancer patients. Blood samples were subjected to both the OBP-401 and CellSearch assays for the detection of CTCs and the results were compared. The recovery rate of the OBP-401 assay was one CTC in 7.5 ml blood combined with high specificity since no CTC was observed in 80 healthy controls. In 50 metastatic patients, 21 patients (42%) were identified as positive with the OBP-401 assay and 27 patients (54%) with the CellSearch assay. The CellSearch assay showed a significantly higher positivity for hormone receptor (HR)-positive tumors (estrogen receptor and/or progesterone receptor-positive tumors) (61%, 25/41, P = 0.012) or CA15-3-positive tumors (69%, 24/35, P = 0.003) than for HR-negative tumors (13%, 1/8) or CA15-3-negative tumors (21%, 3/14), respectively. Contrary, the OBP-401 assay results were similar regardless of their HR status (positive: 44% vs. negative: 38%, P = 0.738) or CA15-3 positivity (positive: 40% vs. negative: 50%, P = 0.523). Of the 27 early stage patients, four patients (15%) were identified by the OBP-401 assay and by the CellSearch assay, respectively, but there was no overlap in the CTCs-positive patients. In conclusion, the OBP-401 assay is comparable to the CellSearch assay in the detection rate of CTCs in both metastatic and early breast cancer patients. However, there was a great discrepancy in patients with CTCs between both assays. The OBP-401 assay may isolate CTCs with other biological characteristics which CTCs detected by the CellSearch assay do not have.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630023     DOI: 10.1007/s10549-011-1603-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  20 in total

1.  A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.

Authors:  Ronald Rodriguez; Shawn E Lupold; Ping Wu; Lori J Sokoll; Tarana A Kudrolli; Wasim H Chowdhury; Rong Ma; Minzhi M Liu
Journal:  Prostate       Date:  2014-07-25       Impact factor: 4.104

Review 2.  Cancer imaging: Gene transcription-based imaging and therapeutic systems.

Authors:  Hyo-eun C Bhang; Martin G Pomper
Journal:  Int J Biochem Cell Biol       Date:  2012-02-10       Impact factor: 5.085

3.  Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study.

Authors:  Melody Ju; Gary D Kao; David Steinmetz; Sanjay Chandrasekaran; Stephen M Keefe; Thomas J Guzzo; John P Christodouleas; Stephen M Hahn; Jay F Dorsey
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

Review 4.  CTC analysis: an update on technological progress.

Authors:  Izhar S Batth; Abhisek Mitra; Sierra Rood; Scott Kopetz; David Menter; Shulin Li
Journal:  Transl Res       Date:  2019-07-11       Impact factor: 7.012

5.  Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer.

Authors:  Hiroaki Ito; Noriko Yamaguchi; Manabu Onimaru; Satoshi Kimura; Tohru Ohmori; Fumihiro Ishikawa; Jun Sato; Shun Ito; Haruhiro Inoue
Journal:  Oncol Lett       Date:  2016-10-11       Impact factor: 2.967

Review 6.  Using circulating tumor cells to inform on prostate cancer biology and clinical utility.

Authors:  Jing Li; Simon G Gregory; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Crit Rev Clin Lab Sci       Date:  2015-06-16       Impact factor: 6.250

Review 7.  Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Authors:  I S Batth; A Mitra; S Manier; I M Ghobrial; D Menter; S Kopetz; S Li
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 8.  Circulating tumor cell isolation, culture, and downstream molecular analysis.

Authors:  Sandhya Sharma; Rachel Zhuang; Marisa Long; Mirjana Pavlovic; Yunqing Kang; Azhar Ilyas; Waseem Asghar
Journal:  Biotechnol Adv       Date:  2018-03-17       Impact factor: 14.227

9.  Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells.

Authors:  Jun Kimura; Hidetaka A Ono; Takashi Kosaka; Yoji Nagashima; Shuichi Hirai; Shigeo Ohno; Kazunori Aoki; Davydova Julia; Masato Yamamoto; Chikara Kunisaki; Itaru Endo
Journal:  Cancer Sci       Date:  2013-07-03       Impact factor: 6.716

10.  Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results.

Authors:  Jay F Dorsey; Gary D Kao; Kelly M MacArthur; Melody Ju; David Steinmetz; E Paul Wileyto; Charles B Simone; Stephen M Hahn
Journal:  Cancer       Date:  2014-09-19       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.